Finally, isatuximab also induces indirect antitumor activity through the elimination of CD38+ immunosuppressive Treg cells [9] and an “in vivo vaccination” effect against CD38 as well as other MM-associated antigens [14]. Here, CD38 is linked to Miyoshi myopathy.